Effect of More Expedited Carotid Intervention on Recurrent Events

This study shows the benefit of reducing waiting time between acute events and intervention in patients with severe symptomatic carotid stenosis. Its outcomes support the efforts to reduce patient management. Moreover, it could be used as an indicator of clinical practice quality.

Claves para mejorar la productividad en la sala de cateterismoThe risk of recurrent events after an ischemic event is significantly higher in the early phase because of extracranial carotid stenosis, which is why guidelines recommend a short delay (to perform either endarterectomy or stenting).

 

Data on all endarterectomy and all stenting on symptomatic stenosis patients were obtained from the Swedish Vascular Registry between 2008 and 2015. Data included all secondary events occurring after the presenting event up to 30 days follow up with inclusion of all pre- and post-intervention recurrences.


Read also: Safety of Early Carotid Artery Stenting in Symptomatic Patients.


Primary end point was recurrent cerebral ischemic event occurring after the presenting event up to 30 days of post-operative follow up.

 

The study looked at 6814 patients and showed a reduction of recurrent ischemic events (31% in 2008/09 to 21% in 2014/15; p=0.01) and, in parallel, mean time from index event to intervention was reduced from 13 to 7 days.


Read also: Is Stage 1 Hypertension as Defined in ACC/AHA Guidelines Associated with Any Events?


The proportion of recurrent events during waiting time was reduced from 25% to 18% (p<0.01) while periprocedural events (death and stroke) were 3.6%, and improved slightly during the studied period.

Conclusion

A substantial reduction of recurrent events is observed when mean waiting time between index procedure and intervention (endarterectomy or stenting) is reduced. This reduction of events during waiting time is in no way counterbalanced by an increase in periprocedural events.

Original title: Effect of More Expedited Carotid Intervention on Recurrent Ischaemic Event Rate: A National Audit.

Reference: Björn Kragsterman et al. Eur J Vasc Endovasc Surg (2018), article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...